$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Topoisomerases represent a class of DNA-modifying enzymes that attract high research and clinical interest, being the target of small-molecule compounds with potential effect in anticancer treatment or in the combat of infectious diseases. Moreover, the activity of human TOP1 has proven to be an effective biomarker of cancer prognosis and treatment18,19,23. Although it is the TOP1 activity that influences the efficacy of a chemotherapeutic inhibitor26, it is frequently the quantity of DNA-RNA or the amount of TOP1 that is assessed in clinical settings. This is due to the lack of fast, easy, and gel-based free tools that can provide accurate and precise quantification of topoisomerase activity in every laboratory settings.
Here, a protocol for the REEAD assay allowing the measurement of TOP1 activity in a gel-free manner is described. In this protocol, purified TOP1 or crude extract from cells is incubated with a specially designed DNA dumbbell-shaped substrate which, upon cleavage/ligation mediated by TOP1 is converted into a closed, circular molecule. The circles are then hybridized onto a glass surface and amplified by RCA. To allow for ease-of-use in the performing of reactions happening on the slide, a silicone grid is attached to the glass, making individual wells where the reactions take place. In this way, the protocol takes advantage of a multiwell system-a silicone grid-called wellmaker.
The protocol was used to detect the activity of recombinant TOP1 and TOP1 extracted from colorectal adenocarcinoma cells Caco2, used as an example. Moreover, as an example of REEAD to be used as a drug screening tool, the protocol was used to detect TOP1 activity inhibition by the well-known TOP1 inhibitor CPT24,25. The assay was coupled with different readout methods-fluorescence microscopy, which gives a high sensitivity, and a fluorescence scanner, chemiluminescence, or colorimetric, which require less specialized equipment and training. The highly sensitive fluorescence microscope readout has the limitations of the need for a good-quality fluorescence microscope setting, skilled personnel, and time-consuming image acquisition and analysis.
For these reasons, the fluorescence scanner readout that allows faster acquisition and analysis even if at the expense of the sensitivity is presented. In case of the lack of a fluorescence scanner, two excellent alternatives, chemiluminescence and colorimetric readout methods, can be considered. Both methods are fast and simple, requiring no expensive equipment or specialized training. In all the readout formats, REEAD has many advantages compared to the state-of-the-art assays, which are more time-consuming, gel-based (with the requirements of intercalating agents), and less directly quantitative. However, there are a few critical steps in the presented protocol. When handling the drug screening, the time points, the drug concentration, and the ratio of TOP1 amount/DNA substrate should be optimized compared to the described settings optimized for CPT. The drug can be investigated performing a preincubation with the DNA substrate or a preincubation with the TOP1 enzyme. This can give valuable information about the ability of the molecule to inhibit TOP1 and offer insight of the drug mechanism of action.
Moreover, if experiencing low or absent signals, this is most likely due to an inefficient lysis of the crude sample or a degradation of TOP1 in the extract due to improper use of protease inhibitors. In addition, this can also be due to inadequate storage of the important assay components, such as recombinant TOP1, phi29 polymerase, nucleotides, substrate, and primer. Finally, repeated freeze-thaw cycles of the oligonucleotides should be avoided, as this dramatically affects the assay performance. When crude extract is used, the extraction efficiency of the specific biological sample needs to be optimized and the amount and activity of TOP1 may vary from the example reported here. For this reason, every crude extract to be tested will require a titration for the identification of the assay detection limit and range of sensitivity when using that particular sample. The protocol has been optimized for the detection of human TOP1. The activity of other eukaryotic TOP1s can be measured, but the NaCl concentration and incubation time might need to be optimized according to the enzyme purification method and optimal enzyme activity. More circularized substrates will result from prolonged incubation, whereas fewer circularized substrates will result from shortened incubation.
In addition to the presented applications, REEAD allows for the measurement of the TOP1 activity in crude extracts from small biopsies from cancer patients18, the prediction of the cytotoxic anticancer effect of CPT in cancer cell lines20,21,22, and even the detection of the enzyme activity in single cells20,21. Moreover, the presented REEAD setting using the wellmaker enables multiwell-based drug screening of libraries of synthetic or natural compounds. In addition to this, a modified version of the REEAD assay, called REEAD C/L, has been developed. This setup enables separate investigations of the cleavage and ligation steps of the TOP1 reaction27. With the REEAD C/L, it is possible to determine the mechanism of action of small molecule inhibitors and characterize them as TOP1 catalytic inhibitors with potential antiparasitic effects28 or as TOP1 poisons to be used for anticancer treatment24,25. Finally, with specific redesign of the DNA substrates to match the different requirements (for DNA binding or cleavage-ligation) of other TOP1 enzymes, REEAD has also been used for the detection of infectious diseases (such as in the case of Plasmodium falciparum, causing malaria29), or Leishmania donovani and Monkeypox virus (data not shown). Or, it can be used to identify small molecule compounds with antipathogenic effects. The presented protocol provides scientists in the TOP1 field an easy method to detect enzyme activity with little to no optimization and with the possibility to be adapted to even wider applications in the future.